First-line nivolumab plus ipilimumab in kidney cancer patients without nephrectomy
A recent post hoc analysis of the CheckMate 214 trial [...]
A recent post hoc analysis of the CheckMate 214 trial [...]
A recent study looked at the efficacy and safety of [...]
A recent study published in Journal of Clinical Medicine this [...]
Renal medullary carcinoma (RMC) is an extremely rare and aggressive [...]
The Scottish Medicines Consortium (SMC) has approved the use of [...]
This phase Ib study reports the results of a combination [...]
This report looked at the results from 4 studies comparing [...]
The use of two medicines together (combination therapies) for previously [...]
Kidney cancers frequently have mutations in the von Hippel-Lindau (VHL) [...]
Ipilimumab plus nivolumab is a standard first-line treatment for patients [...]